1 / 19

Optimal Medical Management of ACS

Optimal Medical Management of ACS. Khawar Kazmi. Inflammation. Lipids. Quiescent Plaque. Plaque rupture. Platelets and thrombin. Thrombus. Thrombosis. ACUTE CORONARY SYNDROME. PATHOGENESIS. ACUTE CORONARY SYNDROME. Optimal Management. Supportive Specific.

lynda
Download Presentation

Optimal Medical Management of ACS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Optimal Medical Management of ACS Khawar Kazmi

  2. Inflammation Lipids Quiescent Plaque Plaque rupture Platelets and thrombin Thrombus Thrombosis ACUTE CORONARY SYNDROME PATHOGENESIS

  3. ACUTE CORONARY SYNDROME Optimal Management Supportive Specific • Oxygen • Pain relief • Beta blockers • Nitrates • Anti Platelets • Anti Coagulants It is crucial to ensure prompt recognition and rapid delivery of care

  4. ACUTE CORONARY SYNDROME Optimal Management DUAL ANTI PLATLET Clopidogrel • Early use in all cases as benefit in all risk categories with or without revascularization* • Loading dose 300 vs. 600mg# • Reloading in NSTMI prior to PCI • No benefit in stable angina+ • CURE, CREDO Trials • ARMYDA-2 Trial • CHARISMA Trial

  5. ACUTE CORONARY SYNDROME Optimal Management ClopidogrelResistance • Resistance vs. Treatment Failure: “NONRESPONSE” • Definite entity but wide variation (4 – 30%) • Variable response to ADP • Genetic Variability • Positive interaction with Omega 3* *J Am Coll Cardiol. 2010

  6. ACUTE CORONARY SYNDROME Optimal Management Clopidogrel and PPIs • Data on PPI plus Clopidogrel show inconsistent risk of adverse outcome • Meta Analysis show no increased risk of CV events or mortality Ailment Pharmacol Ther. 2010 • Adding PPI to Clopidogrel increases re-hospitalization for • MI/ stenting • Subgroup analysis reveals significant risk specifically with pantaprazole • Arch Intern Med. 2010

  7. ACUTE CORONARY SYNDROME Optimal Management Clopidogrel : Duration and cessation • Similar rates of cardiac death, MI regardless of stopping clopidogrel after 12 months • Trend towards higher rates of MI, Stroke, or all cause death with prolonged dual therapy • Under powered study does not provide definite answer to issue of optimal duration • N Engl J Med. 2010 • Halting Clopidogrel in ACS patients more than double risk of death / MI within 90 days vs. 91 – 360 days • Tapering may help but more research needed • Circ Cardiovasc Qual Outcomes. 2010

  8. ACUTE CORONARY SYNDROME Optimal Management PRASUGREL • More effective esp. in patients with Clopidogrel Non Response • Better primary efficacy endpoint (9.9 vs. 12.1%.. Triton- TIMI 38) • Increased Bleeding including life threatening (2.4 vs. 1.8%) But mainly in patients with H/O stroke or TIA, patients >75 years and those with body weight <60kg

  9. ACUTE CORONARY SYNDROME Optimal Management Ticagrelor • Ticagrelor more effective than Clopidogrel without increasing bleeding* • Lowers CV death, MI, Stroke vs. Clopidogrel in STEMI • Antiplatelet effect of Ticagrelor kicks in more rapidly than high dose Clopidogrel** • Ticagrelor improves platelet inhibition regardless of initial Clopidogrel response*** • Urgent bypass pts on prior Ticagrelor have better survival than those on Clopidogrel* *PLATO Trial. Lancet 2010 ** The ONSET/OFFSET Study ***Respond Study. Circulation 2010

  10. ACUTE CORONARY SYNDROME Optimal Management CILOSTAZOL • Triple therapy lowers platelet response on VerifyNow assay but • Results do not translate to lower ischemic events in DES patients CILON- T trial

  11. ACUTE CORONARY SYNDROME Optimal Management Anticoagulants • LMWH vs. UFH • Enoxaparinvs. Foundaparinaux • Bivalirudin vs. GPIIb/IIIa plus Heparin

  12. Bleeding 1988 ASA 2003 ASA+ LMWH + Clopidogrel + Intervention 1998 ASA+ Heparin+ Anti-GPIIb/IIIa 1992 ASA+ Heparin 16-20% 12-15% 8-12% 6-10% Death / MI 4-8% Benefit-to-Risk Ratio of Antithrombotics in UA/NSTEMI in the Last Decade: Increased Efficacy at the Price of Increased Bleeding

  13. Major Bleeding is Associated with an Increased Risk of Hospital Death in ACS Patients GRACE Registry in 24,045 ACS patients 40 No Yes In hospital major bleeding OR (95% CI) 1.64 (1.18 to 2.28*) ** 30 ** ** 22.8 ** 18.6 20 In-hospital death (%) 16.1 15.3 10 7.0 5.3 5.1 3.0 0 Overall ACS NSTEMI STEMI UA *After adjustment for comorbidities, clinical presentation and hospital therapies **p<0.001 for differences in unadjusted death rates Moscucci et al. Eur Heart J 2003;24:1815-23

  14. Strong, Independent Association Between Bleeding and Death, MI and Stroke OASIS Registry, OASIS-2, CURE N = 34,126 Eikelboom JW et al. Circulation 2006;114(8):774-82.

  15. The OASIS 5 Study OASIS 5 N Engl J Med 2006;354:1464-76

  16. In Patients with UA/NSTEMI OASIS 5 Fondaparinux was as effective as enoxaparin in reducing the composite of death, MI or refractory ischemia at day 9 Fondaparinux significantly reduced the risk of death by 17% compared with enoxaparin at day 30 and this benefit was maintained at 6 months Fondaparinux was associated with a significant 48% reduction in the risk of major bleeding versus enoxaparin Consistent results were observed in every subgroup examined Fondaparinux consistently reduced the rate of major bleeding irrespective of renal function and baseline risk The lower rate of bleeding in fondaparinux-treated patients translated into a lower mortality rate OASIS 5 Investigators. N Engl J Med 2006;354:1464-76

  17. ACUTE CORONARY SYNDROME Optimal Management Bivalirudin • Bivalirudin alone compared to heparin and GPIIb/IIIa inhibitors resulted in comparable rates of MI and stent thrombosis, with significantly reduced rates of major bleeding and mortality(all cause and cardiac) • At 2 years • 36% reduction in major bleeding and 25% reduction in reinfarction • 41% reduction in cardiac mortality and 25% reduction in all cause mortality • But the benefits were variable among the sub groups • HORIZON AMI Trial

  18. 2007 AHA/ACC UA/NSTEMI Guidelines: Recommendation for Anticoagulation Class I Recommendations • For patients in whom an invasive strategy is selected, regimens with established efficacy include fondaparinux, enoxaparin, UFH or bivalirudin • For patients in whom a conservative strategy is selected, regimens with established efficacy include fondaparinux, enoxaparin or UFH • In patients in whom a conservative strategy is selected and who have an increased risk of bleeding, fondaparinux is preferable. LOA B for fonda and bivalirudin; A for enoxaparin or UFH JACC 2007;50 (7):e1-157

  19. I will stop here but we will continue our search for optimal medical therapy thank you

More Related